Director, Global Bio-innovations for the Biosciences Division, Life Science Solutions Group
Clinton, New Jersey, United States
Contact Info
933 followers
500+ connections
Activity
Experience
Education
Publications
-
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.
Proceedings of the National Academy of Sciences of the United States of America
Mutation in leucine-rich-repeat kinase 2 (LRRK2) is a common cause of Parkinson disease (PD). A disease-causing point mutation R1441H/G/C in the GTPase domain of LRRK2 leads to overactivation of its kinase domain. However, the mechanism by which this mutation alters the normal function of its GTPase domain [Ras of complex proteins (Roc)] remains unclear. Here, we report the effects of R1441H mutation (RocR1441H) on the structure and activity of Roc. We show that Roc forms a stable monomeric…
Mutation in leucine-rich-repeat kinase 2 (LRRK2) is a common cause of Parkinson disease (PD). A disease-causing point mutation R1441H/G/C in the GTPase domain of LRRK2 leads to overactivation of its kinase domain. However, the mechanism by which this mutation alters the normal function of its GTPase domain [Ras of complex proteins (Roc)] remains unclear. Here, we report the effects of R1441H mutation (RocR1441H) on the structure and activity of Roc. We show that Roc forms a stable monomeric conformation in solution that is catalytically active, thus demonstrating that LRRK2 is a bona fide self-contained GTPase. We further show that the R1441H mutation causes a twofold reduction in GTPase activity without affecting the structure, thermal stability, and GDP-binding affinity of Roc. However, the mutation causes a twofold increase in GTP-binding affinity of Roc, thus suggesting that the PD-causing mutation R1441H traps Roc in a more persistently activated state by increasing its affinity for GTP and, at the same time, compromising its GTP hydrolysis.
More activity by Mark
-
Outstanding success and another step forward for gene therapy medicine
Outstanding success and another step forward for gene therapy medicine
Shared by Mark Federici
People also viewed
-
Sesha Tekur
Connect -
Nancy Papp Campi
Connect -
Karen Snovel
Director, Business Development & Solution Design at Learning Solutions from Syneos Health (Previously inVentiv Health Learning Solutions)
Connect -
Francesca Foltz
Associate Scientist, Molecular Biology at AMDI Labs
Connect -
Chris Schauder
Connect -
Adam Buckley
Connect -
Lindsey Harp
Connect -
Jim Koers
Connect -
Emelie Johansson
Connect -
Rachael Felberbaum, Ph.D.
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Mark Federici in United States
-
Mark Federici
-
Mark Federici
Underwriting and Rescission/Medical Mis-Rep. Consultant
-
Mark Federici
VP at Cadent Gorp
-
Mark Federici
Gm at SMILEYS LANDSCAPE
8 others named Mark Federici in United States are on LinkedIn
See others named Mark Federici